Objective:
Detection of IgG positivity towards NF155, NF186, NF140, CNTN-1, CNTN-1/CASPR-1 in a CIDP patients (18-870, 16-047)
SAMPLES:
- 18-870 (Test all)
- 16-047 (Test CNTN-1, CNTN-1/CASPR-1)
- Healthy control
- Positive controls:
- NF155: LAC
- NF140/186: 16-069
- CNTN-1: 15-198
- CNTN-1/CASPR-1:17-595
ICC NF155, NF186 and NF140 ICC:
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 for IgG with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 IgM (1/1000).
- Vectashield mounting medium
ICC CNTN-1:
- Blocking solution: Rabbit serum diluted 1/40 in PBS.
- Patient’s sera diluted 1/100 for IgG with rabbit serum 1/40.
- Primary antibody: AF904 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 IgM (1/1000)
- Vectashield mounting medium.
ICC CNTN-1/CASPR-1:
- Blocking solution: Goat serum diluted at 5% in PBS.
- Patient’s sera diluted 1/100 for IgG with goat serum 5% in PBS.
- Primary antibody: Ab 1336341 diluted 1/250
- Secondary antibodies: GAR488 + GAH 594 IgG (1/1000)
- Vectashield mounting medium
RESULTS:
16-047 was positive to CNTN-1/CASPR-1
18-870 was negative
Positive controls were positive
